Related Experiment Video
Updated: May 11, 2026
08:21
Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
Published on: July 21, 2023
Pharmacogenomics and cardiovascular disease.
1Division of Clinical Pharmacology, Vanderbilt University School of Medicine, 1285 Medical Research Building IV, Nashville, TN 37232, USA. peter.e.weeke@vanderbilt.edu
Current Cardiology Reports
|May 22, 2013
Summary
Genomic variations influence how patients respond to cardiovascular drugs, impacting treatment effectiveness and toxicity. Understanding these genetic factors is key to personalizing medicine and improving patient outcomes.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Genetics
Background:
- Drug response variability is common in therapeutics.
- Genomic variations significantly contribute to differing drug responses.
- Cardiovascular therapies serve as a model for pharmacogenomics research.
Purpose of the Study:
- To review the current state of cardiovascular pharmacogenomics.
- To explore the role of genetic variants in drug response and toxicity.
- To discuss the clinical application of genetic information in cardiovascular treatment.
Main Methods:
- Review of existing literature on cardiovascular pharmacogenomics.
- Analysis of genetic variants affecting commonly used cardiovascular drugs (e.g., clopidogrel, warfarin, statins).
- Examination of genomic approaches to identify drug response mechanisms and toxicities.
Main Results:
- Established critical pathways and genetic loci modulating responses to cardiovascular drugs.
- Identified genetic variants linked to drug toxicities.
- Informed changes in drug product labels and development of clinical guidelines.
Conclusions:
- Cardiovascular pharmacogenomics has advanced significantly.
- Genetic information is increasingly being integrated into clinical decision-making.
- Further deployment of genetic variants can personalize cardiovascular therapy.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...